WHO vaccine-preventable diseases: monitoring system. 2019 global summary

Last updated 10-December-2019 (data as of 10-December-2019)
Next overall update June 2020
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 9'1801 Infant (under 12 months) mortality rate: 122
GDP / capita (US$): 19'9691 Child (under 5 years) mortality rate: 132

Population data in thousands3

  2018  2017  2016  2015  2014  2000  1990  1980 
Total population 126'191  124'777  123'333  121'858  120'355  98'900  83'943  67'761 
Births 2'220  2'235  2'249  2'262  2'273  2'359  2'418  2'360 
Surviving infants 2'191  2'204  2'218  2'230  2'240  2'307  2'331  2'238 
Pop. less than 5 years 11'139  11'226  11'264  11'234  11'237  11'451  11'516  11'011 
Pop. less than 15 years 33'512  33'614  33'676  33'677  33'707  33'820  32'911  30'335 
Female 15-49 years 67'158  66'461  65'743  65'027  64'304  51'662  41'204  30'022 

Number of reported cases

(Click for retrospective incidence data for Mexico)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  30  68'782  29'730 
Mumps
ChartChart
  3'646  3'399  4'143  27'403 
Pertussis
ChartChart
  783  827  1'029  1'107  955  53  1'078  5'539 
Polio*
  682 
Rubella
ChartChart
  11'751 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  145 
Tetanus (total)**
ChartChart
  23  27  35  27  26  103  381  363 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Mexico)
Vaccine year result method % card seen                                                
BCG 2014  93  MICS   75  96  94  99*  99*  96  99*  67  48 
DTP1 2014  92  MICS   75  90  93  96  99*  99 
DTP3 2014  72  MICS   75  88  85  93  87  87  97  53  44 
IPV1          90  93  96  99* 
HepB_BD          98 
HepB3 2014  82  MICS   75  55  58  93  82  84  97 
Hib3 2014  72  MICS   75  88  85  93  87  87  97 
JapEnc         
MCV1          97  76  97  99*  98  96  75  35 
MCV2          99  62  98  96  96  98 
MenA         
PCV1          89  93  95  92 
PCV2          90  90  94  99*  90 
PCV3 2014  57  MICS   75  88  92  92  99*  94 
Pol3 2014  72  MICS   75  88  85  96  87  87  97  66  91 
Rota1          89  89  91  97 
RotaC 2014  63  MICS   75  77  70  72  81  85 
RCV1          97  76  99*  98 
TT2plus          99*  96  22  78 
PAB          96 
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2020

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Mexico)
BCG
ChartChart
  96  94  99  98  96  99  67  48 
DTP1
ChartChart
  90  93  96  99  95  99  77  69 
DTP3
ChartChart
  88  85  93  87  87  97  53  44 
HepB3
ChartChart
  55  58  93  82  84  97 
HepB_BD
ChartChart
  98  98  98  98  90 
Hib3
ChartChart
  88  85  93  87  87  97 
IPV1
  90  93  96  99 
MCV1
ChartChart
  97  76  96  97  97  96  75  35 
MCV2
ChartChart
  99  62  98  96  95  98 
PCV3
ChartChart
  88  92  92  93  94 
Pol3
ChartChart
  88  85  96  87  87  97  66  91 
RCV1
ChartChart
  97  76  96  97  97  96 
RotaC
ChartChart
  77  70  72  81  85 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 2'463  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 48
From 80 to 89% 15
From 50 to 79% 27
Less than 50% 10
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2018 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTaPHibHepBIPV 2, 4, 6, 18 months; No The hexavalent vaccine was used during 2018 only by the Ministry of Health as a strategy against the shortage of acellular Pentavalent vaccine, the rest of the sector used acellular Pentavalent vaccine to apply the scheme
DTaPHibIPV 2, 4, 6, 18 months; Yes
DTwP 4 years; Yes
HepA_Pediatric 1 year; Yes For children enrolled in nurseries or children's rooms
HepB_Adult 1st contact; Yes >20 years if no vaccine history
HepB_Pediatric birth; 2, 6 months; Yes
HPV 9-11 years; +6 months; Yes and HIV positive females 11-49 years with a scheme of three doses at first contact (0), 6 and 12 months
Influenza_Adult >60 years; Yes and adults with chronic conditions, pregnant women, healthcare workers, other risk groups
Influenza_Pediatric 6-59 months; Yes and children with chronic conditions
MMR 1, 6 years; Yes
MR 1st contact; Yes Children >=10 years with no vaccination history
OPV 6-59 months; Yes Only used in intensive phases (National Health Weeks) for children with at least 2 doses of DTaPHibIPV
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps 65 years; Yes
Rotavirus 2, 4, 6 months; Yes
Td 15 years; Yes as reinforcement for those >10 years
Tdap Yes For pregnant women after week 20 of gestation
Varicella 1 year; Yes children 1 year old enrolled in nurseries or children's rooms
VitaminA 6-59 months; Yes not provided as an integrated manner

Immunizaton indicators

Indicator Expected answer 2018  2017  2016  2015  2014  2013  2012 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2013-2018  2013-2018  2013-2018  2012-2018  2013-2018  2013-2018  2012-2018 
Nº of districts with microplans that include activities to raise immunization coverage number 32  32  32  236    32  236 

System performance

Total Nº districts in country number 2'463  2'446    2'457  2'456  2'440  2'432 
Nº districts with DTP3 coverage >=80% number 1'553  1'390  1'771  1'818  1'135    2'162 
% of districts with DTP3 coverage >=80% From 0 to 100% 63  57    74  46    89 
Nº districts with measles (MCV1) coverage >=95% number 1'343  594  1'177  1'245  1'260    2'031 
% of districts with MCV1 coverage >=95% From 0 to 100% 55  24    51  51    84 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100    100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.